Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial

First- or second-generation EGFR tyrosine kinase inhibitors (EGFR-TKI) have been the first-line treatment for NSCLC harboring EGFR mutation (1-6), however almost all patients inevitably acquire resistance during EGFR-TKI therapy.